Mutant p53-based Personalized Trial Using Decitabine and Arsenic Trioxide on AML/MDS

NCT03855371 · clinicaltrials.gov ↗

PHASE1

Phase

UNKNOWN

Status

5

Enrollment

OTHER

Sponsor class

Conditions

P53 Mutation
Myeloid Malignancy
MDS
Aml

Interventions

DRUG: Decitabine
DRUG: Arsenic Trioxide

Sponsor

Ruijin Hospital